DOCSLIB.ORG

854E676a8992c41df6b1f4f77e5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
854E676a8992c41df6b1f4f77e5 molecules Article Synthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α1A/α1D-Adrenergic Receptor Antagonist with Potential Uroselective Profile Vittorio Canale 1, Aleksandra Rak 2, Magdalena Kota ´nska 2, Joanna Knutelska 2, Agata Siwek 3, Marek Bednarski 2, Leszek Nowi ´nski 2, Małgorzata Zygmunt 2, Paulina Koczurkiewicz 4, Elzbieta˙ P˛ekala 4, Jacek Sapa 2,* and Paweł Zajdel 1 1 Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland; [email protected] (V.C.); [email protected] (P.Z.) 2 Department of Pharmacological Screening, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland; [email protected] (A.R.); [email protected] (M.K.); [email protected] (J.K.); [email protected] (M.B.); [email protected] (L.N.); [email protected] (M.Z.) 3 Department of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland; [email protected] 4 Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland; [email protected] (P.K.); [email protected] (E.P.) * Correspondence: [email protected] Received: 12 July 2018; Accepted: 13 August 2018; Published: 29 August 2018 Abstract: Benign prostatic hyperplasia (BPH) is the most common male clinical problem impacting the quality of life of older men. Clinical studies have indicated that the inhibition of α1A-/α1D adrenoceptors might offer effective therapy in lower urinary tract symptoms. Herein, a limited series of arylsulfonamide derivatives of (aryloxy)ethyl alicyclic amines was designed, synthesized, and biologically evaluated as potent α1-adrenoceptor antagonists with uroselective profile. Among them, compound 9 (3-chloro-2-fluoro-N-([1-(2-(2-(2,2,2-trifluoroethoxy)phenoxy]ethyl)piperidin-4-yl) methyl) benzenesulfonamide) behaved as an α1A-/α1D-adrenoceptor antagonist (Ki(α1) = 50 nM, EC50(α1A) = 0.8 nM, EC50(α1D) = 1.1 nM), displayed selectivity over α2-adrenoceptors (Ki(α2) = 858 nM), and a 5-fold functional preference over the α1B subtype. Compound 9 showed adequate metabolic stability in rat-liver microsome assay similar to the reference drug tamsulosin (Clint = 67 and 41 µL/min/mg, respectively). Compound 9 did not decrease systolic and diastolic blood pressure in normotensive anesthetized rats in the dose of 2 mg/kg, i.v. These data support development of uroselective agents in the group of arylsulfonamides of alicyclic amines with potential efficacy in the treatment of lower urinary tract symptoms associated to benign prostatic hyperplasia. Keywords: arylsulfonamides of alicyclic amines; α1-adrenoceptor antagonists; α1A/B/D receptor selectivity; silodosin; tamsulosin; uroselective activity; benign prostatic hyperplasia 1. Introduction α1-Adrenergic receptors (α1-ARs) belong to the G-protein-coupled receptor superfamily. They generally mediate their actions through Gq/11 proteins, which stimulate the activation of phospholipase C, via generation of the inositol triphosphate and diacylglycerol, liberation of calcium from the endoplasmic reticulum, and/or activation of genes. To date, three subtypes of α1-AR, i.e., α1A, Molecules 2018, 23, 2175; doi:10.3390/molecules23092175 www.mdpi.com/journal/molecules Molecules 2018, 23, 2175 2 of 17 α1B, and α1D have been identified in human tissues [1]. Although these subtypes display high structural homology, they differ in biological structure, tissue distributions, and pharmacological actions [2]. Several studies revealed that α1-AR subtypes are highly expressed in blood vessels—mainly α1B-ARs, in the urogenital area (prostate, urethra, bladder, ureter)—mainly α1A and α1D-ARs, and central nervous systemMolecules 2018 [3]., 23α, 1x -ARs play an important role in the pathogenesis of hypertension2 of and17 benign prostatic hyperplasia (BPH) [4,5]. α1A, α1B, and α1D have been identified in human tissues [1]. Although these subtypes display high An increased α1-adrenergic prostate smooth muscle tone together with enhanced prostate structural homology, they differ in biological structure, tissue distributions, and pharmacological volume are recognized causes of the disease [6]. BPH clinically manifests with lower urinary actions [2]. Several studies revealed that α1-AR subtypes are highly expressed in blood vessels— tract symptomsmainly α (LUTS)1B-ARs, inas the storage urogenital (irritative) area (prostat symptomse, urethra, bladder, (nocturia, ureter)—mainly urgency, α1A incontinence, and α1D-ARs, altered bladder sensations,and central nervous increased system frequency) [3]. α1-ARs or play obstructive an important (voiding) role in the symptoms pathogenesis (hesitancy,of hypertension slow stream, intermittency,and benign splitting, prostatic straining, hyperplasia terminal (BPH) [4,5]. dribble) [7]. Some of them commonly occur secondary An increased α1-adrenergic prostate smooth muscle tone together with enhanced prostate to obstructivevolume symptoms, are recognized and causes result of fromthe disease exaggerated, [6]. BPH clinically spontaneous manifests detrusorwith lower contractions urinary tract (known as bladdersymptoms overactivity) (LUTS) [ as7, 8storage]. BPH (irritative) affects symptoms the majority (nocturia, of men urgency, with incontinence, increasing altered frequency bladder as they get older [9]. LUTS,sensations, if left increased untreated, frequency) result inor significantobstructive impairment(voiding) symptoms of quality (hesitancy, of life andslow leadstream, to long-term complications,intermittency, such as splitting, recurrent straining, urinary terminal tract dribbl infectionse) [7]. Some or renal of them insufficiency commonly occur [10 secondary]. to obstructive symptoms, and result from exaggerated, spontaneous detrusor contractions (known as α Despitebladder several overactivity) classes of[7,8]. BPH BPH medications affects the majority available, of men studies with increasing have shown frequency that as 1they-adrenolitics get are consideredolder as the [9]. first-lineLUTS, if left drug untreated, treatment result [in11 significant]. It has beenimpairment suggested of quality that of enhanced, life and lead three-to-nine-fold to long- greater expressionterm complications, of α1A -such and as αrecurrent1D-ARs urinary in an tract enlarged infections prostate or renal insufficiency and bladder [10]. neck, comparing to Despite several classes of BPH medications available, studies have shown that α1-adrenolitics healthy tissue, remains in strong contribution with LUTS occurrence [12]. Consequently, an α1A- and are considered as the first-line drug treatment [11]. It has been suggested that enhanced, three-to- α -AR blockade relieves obstructive and voiding symptoms by relaxation of the smooth muscle in 1D nine-fold greater expression of α1A- and α1D-ARs in an enlarged prostate and bladder neck, comparing the prostateto healthy and bladder tissue, remains detrusor, in strong respectively contributi [on13 with]. LUTS occurrence [12]. Consequently, an α1A- In contrast,and α1D-AR a blockadeblockade relieves of α 1Bobstructive-ARs, which and voiding are predominantlysymptoms by relaxation expressed of the smooth in vascular muscle smooth muscle [14in], the results prostate in and vasodilation bladder detrusor, of blood respectively vessels [13]. leading to cardiovascular side effects, especially In contrast, a blockade of α1B-ARs, which are predominantly expressed in vascular smooth α orthostaticmuscle hypotension [14], results [15 in]. vasodilation The old of1-adrenolitics, blood vessels leading bearing to cardiovascular quinazoline side scaffold, effects, especially i.e., doxazosin or terazosin,orthostatic display nonspecific hypotension [15]. interaction The old α1 with-adrenolitics, all α1-AR bearing subtypes quinazoline [5]. scaffold, On the i.e., other doxazosin hand, or naftopidil, tamsulosin,terazosin, and silodosin display nonspecific (Figure1 interaction), displaying with all relatively α1-AR subtypes high [5].α1A On- andthe otherα1D -ARhand, subtypenaftopidil, selectivity, effectivelytamsulosin, relieve symptoms and silodosin related (Figure to 1), BHP/LUTS displaying relatively disease high without α1A- and undesirable α1D-AR subtype side selectivity, effects on blood effectively relieve symptoms related to BHP/LUTS disease without undesirable side effects on blood pressure [16pressure–18]. [16–18]. Figure 1. Chemical structures of selective α1A- and α1D-AR antagonists. Figure 1. Chemical structures of selective α1A- and α1D-AR antagonists. Integrating a concept of arylpiperazine biomimetics recently adapted for development of Integratingselective a conceptand potent of 5-HT arylpiperazine7R antagonists biomimetics [19], we explored recently the adaptedcommon forchemical development space with of selective tamsulosin to propose modifications leading to increased α1A-AR properties. Associating and potent 5-HT R antagonists [19], we explored the common chemical space with tamsulosin arylsulfonamide7 and aryloxylalkyl fragments identified compound I, which behaved as an α1A-AR to proposeantagonist modifications and displayed leading a moderate to increased selectivityα receptor1A-AR properties.profile over α1B-AR Associating subtype [20]. arylsulfonamide In an and aryloxylalkylattempt to fragmentsfurther increase identified
Load more

Recommended publications
  • Study Protocol and Statistical Analysis Plan
    Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 RANDOMIZED CONTROLLED PILOT STUDY USING PROPRANOLOL TO DECREASE GENE EXPRESSION OF STRESS-MEDIATED BETA- ADRENERGIC PATHWAYS IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS Version 3.0 Principal Investigator: Jennifer M. Knight, MD Medical College of Wisconsin 8701 Watertown Plank Road Milwaukee, WI 53226 Telephone: 414-955-8908 Fax: 414-955-6285 Email: [email protected] Co-Investigator: J. Douglas Rizzo, MD, MS CIBMTR Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-0700 Fax: 414-805-0714 Email: [email protected] Co-Investigator: Parameswaran Hari, MD, MS Froedtert and the Medical College of Wisconsin Clinical Cancer Center 9200 W. Wisconsin Avenue Suite C5500 Milwaukee, WI 53226 Telephone: 414-805-4600 Fax: 414-805-4606 Email: [email protected] Consultant Steve W. Cole, PhD and Statistician: UCLA-David Geffen School of Medicine 10833 LeConte Ave 11-934 Factor Bldg Los Angeles, CA 90095-1678 Telephone: 310-267-4243 Email: [email protected] 1 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 Sponsor: Medical College of Wisconsin Funding Sponsor: This project has an offer of sponsorship from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. 2 Propranolol and Gene Expression in HCT Protocol v3.0, January 15, 2016 PROTOCOL SYNOPSIS Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients Principal Investigator: Jennifer M. Knight, MD Study Design: This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of individuals receiving an autologous hematopoietic stem cell transplant (HCT) for multiple myeloma.
    [Show full text]
  • Avoid the Stop and Go of BPH Start and Stay on RAPAFLO® for BPH Symptom Relief
    Avoid the Stop and Go of BPH Start and Stay on RAPAFLO® for BPH Symptom Relief Using RAPAFLO® RAPAFLO® is available only by prescription and is approved to treat male urinary symptoms due to BPH, also called an enlarged prostate. RAPAFLO® should not be used to treat high blood pressure. Important Safety Information Who should not take RAPAFLO® (silodosin) capsules? Do not take RAPAFLO® if you: • have certain kidney problems. • have certain liver problems. Please see additional Important Safety Information throughout this brochure and accompanying full Prescribing Information in pocket. Have BPH symptoms? What they may mean Enlarged prostate— uncomfortable but not uncommon Your doctor has diagnosed you with having BPH, benign prostatic hyperplasia, also known as an enlarged prostate. As men age, having BPH is not unusual. In fact, BPH is the most common prostate problem for men over 50. It affects about 50% of men aged 51-60 and up to 90% of men over 80. The prostate is about But it can grow to the size of a walnut the size of a baseball. in younger men. BLADDER The prostate is located below the bladder and surrounds the urethra, the tube that carries urine from the bladder. BPH symptoms occur when the “smooth” muscle of the prostate squeezes the urethra. This, in turn, can affect your bladder URETHRA control. Unfortunately, there is little you can do PROSTATE to avoid BPH. 2 Is BPH linked to prostate cancer? No. While many men share this belief, BPH is not linked to prostate cancer, and men with BPH are not more likely to get prostate cancer.
    [Show full text]
  • 2021 Step Therapy Criteria
    SelectHealth Advantage 2021 Step Therapy Criteria Step Therapy Group Drug Name Criteria ACNE ADAPAL/BEN P Previous trial on at least ONE: AZELEX Generic topical acne treatment TRETINOIN ACTONEL RISEDRON SOD Previous trial on: RISEDRONATE alendronate ADAPALENE ADAPALENE Previous use of non-micronized tretinoin TAZAROTENE ANTICONVULSANT APTIOM Previous trial on at least TWO of the following: SPRITAM carbamezapine, divalproex, epitol, ethosuximide, felbamate, lamotrigine, XCOPRI levetiracetam, oxcarbazepine, phenytoin, tiagabine, topiramate, valproic acid, zonisamide ANTIDEPRESSION APLENZIN Previous trial on at least TWO of the following: EMSAM bupropion, citalopram, escitalopram, fluoxetine, fluvoxamine, maprotiline, FETZIMA mirtazapine, paroxetine, sertraline, venlafaxine, desvenlafaxine PEXEVA TRINTELLIX VIIBRYD ANTIPSYCHOTIC ARISTADA Previous trial on at least ONE of the following: ASENAPINE aripiprazole, clozapine, fluoxetine-olanzapine, haloperidol, olanzapine, FANAPT quetiapine, risperidone, ziprasidone LATUDA PALIPERIDONE SECUADO VRAYLAR BELSOMRA BELSOMRA Previous trial on at least ONE of the following: zaleplon, zolpidem, eszopiclone BUDESONIDE BUDESONIDE TAB Previous trial of ONE of the following: Mesalamine, Pentasa CADUET AMLOD/ATORVA Previous trial on at least ONE of the following: atorvastatin, lovastatin, pravastatin, simvastatin AND Previous trial on: amlodipine Updated 8/25/2021 1 SelectHealth Advantage 2021 Step Therapy Criteria Step Therapy Group Drug Name Criteria CAPEX CAPEX Previous trial on: clobetasol shampoo OR ciclopirox
    [Show full text]
  • Silodyx, INN-Silodosin
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Silodyx 4 mg hard capsules Silodyx 8 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Silodyx 4 mg hard capsules Each hard capsule contains 4 mg silodosin. Silodyx 8 mg hard capsules Each hard capsule contains 8 mg silodosin. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule. Silodyx 4 mg hard capsules Yellow, opaque, hard gelatin capsule, size 3 (approximately 15.9 x 5.8 mm). Silodyx 8 mg hard capsules White, opaque, hard gelatin capsule, size 0 (approximately 21.7 x 7.6 mm). 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men. 4.2 Posology and method of administration Posology The recommended dose is one capsule of Silodyx 8 mg daily. For special patient populations, one capsule of Silodyx 4 mg daily is recommended (see below). Elderly No dose adjustment is required in the elderly (see section 5.2). Renal impairment No dose adjustment is required for patients with mild renal impairment (CLCR ≥ 50 to ≤ 80 mL/min). A starting dose of 4 mg once daily is recommended in patients with moderate renal impairment (CLCR ≥ 30 to < 50 mL/min), which may be increased to 8 mg once daily after one week of treatment, depending on the individual patient’s response. The use in patients with severe renal impairment (CLCR < 30 mL/min) is not recommended (see sections 4.4 and 5.2). Hepatic impairment No dose adjustment is required for patients with mild to moderate hepatic impairment.
    [Show full text]
  • Treatment Options for Motor and Non-Motor Symptoms of Parkinson’S Disease
    biomolecules Review Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease Frank C. Church Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] Abstract: Parkinson’s disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopamin- ergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson’s (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine ago- nist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson’s disease.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Development and Validation of High Performance LCMS Methods For
    na al A lyti tic ca u l e C c h a e Nair et al., Pharm Anal Chem 2016, 3:1 m m r i s a Pharmaceutical Analytical t DOI: 10.4172/2471-2698.1000118 h r y P ISSN: 2471-2698 Chemistry Research Article Open Access Development and Validation of High Performance LCMS Methods for Estimation of Silodosin and Silodosin β-D-Glucuronide in Human Plasma Sheeba Manoj Nair1*, Ravi Kumar P1, Malini Sharma1 and Denish Karia2 1Semler Research Center, Bangalore, Karnataka, India 2Department of Chemistry, Patel JDK Science College, Borsad, Gujarat, India Abstract The aim of present study is to development and validation of analytical methods for estimation of Silodosin and Silodosin β-D-Glucuronide in human plasma in API, method in LCMS. Silodosin is a prescription medication that acts as an alpha-adrenergic blockers used in the treatment for men with benign prostatic hyperplasia, presently commercially available and marketed as Rapaflo in USA and Rapilif, Silodal in other countries worldwide. Drug showed linearity in the concentration range of 0.502 ng/ml to 207.376 ng/ml for Silodosin and 4.121 ng/ml to 302.836 ng/ml for Silodosin β-D-Glucuronide with correlation coefficient consistently greater than 0.99 for Silodosin and Silodosin β-D-Glucuronide. Mass parameters, 496.2/261.0 and 672.2/479.3/261.2 were chosen for analysis by Solid phase extraction method. Different validation parameters to be considered are Accuracy, Precision, Repeatability, Intermediate Precision, Specificity, Detection Limit, Quantitation Limit, and Linearity Range. The results were found to be acceptable as per the guidelines of International Conference on Harmonization (ICH).
    [Show full text]
  • Blockers in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
    Journal name: Clinical Interventions in Aging Article Designation: Letter Year: 2015 Volume: 10 Clinical Interventions in Aging Dovepress Running head verso: Zhu et al Running head recto: Alpha -blockers for benign prostatic hyperplasia open access to scientific and medical research 1 DOI: http://dx.doi.org/10.2147/CIA.S82435 Open Access Full Text Article LETTER Personalized therapeutics of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Ling-ling Zhu1 Dear editor Zhi-jun Feng2 We read with great interest the multicenter, prospective, comparative cohort study by Quan Zhou3 Zhang et al1 who suggested that patients with uncontrolled or untreated hypertension 1Geriatric VIP Ward, Division and lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/ of Nursing, 2Department of Urology LUTS) should be warned about a decrease in blood pressure on initiation of alfuzosin Surgery, 3Department of Pharmacy, the Second Affiliated Hospital, School 10 mg therapy alone or concomitantly with antihypertensive medication. Here we of Medicine, Zhejiang University, discuss and share our perspectives on this issue. Hangzhou, People’s Republic of China α1-blockers are the most frequently prescribed medical therapy in the treatment of BPH/LUTS. A number of -blockers (alfuzosin, doxazosin, terazosin, tamsulosin, naf- For personal use only. α1 topidil, silodosin) have been approved for the treatment of BPH throughout the world; however, they exhibit different selectivity toward α1-adrenoceptor (AR) subtypes. Three types of α1-AR subtypes (α1A, α1B, and α1D) are found in human tissue. The α1A subtype is located in the human prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, and mediates contraction of the smooth muscle in these tissues.
    [Show full text]
  • Interactions with HBV Treatment
    www.hep-druginteractions.org Interactions with HBV Treatment Charts revised September 2021. Full information available at www.hep-druginteractions.org Page 1 of 6 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ADV, Adefovir; ETV, Entecavir; LAM, Lamivudine; PEG IFN, Peginterferon; RBV, Ribavirin; TBV, Telbivudine; TAF, Tenofovir alafenamide; TDF, Tenofovir-DF. ADV ETV LAM PEG PEG RBV TBV TAF TDF ADV ETV LAM PEG PEG RBV TBV TAF TDF IFN IFN IFN IFN alfa-2a alfa-2b alfa-2a alfa-2b Anaesthetics & Muscle Relaxants Antibacterials (continued) Bupivacaine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cloxacillin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Cisatracurium ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dapsone ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoflurane ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Delamanid ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ketamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ertapenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Nitrous oxide ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Erythromycin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Propofol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Ethambutol ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Thiopental ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Flucloxacillin ◆ ◆ ◆ ◆ ◆ ◆ Tizanidine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Gentamicin ◆ ◆ ◆ ◆ ◆ ◆ Analgesics Imipenem ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aceclofenac ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Isoniazid ◆ ◆ ◆ ◆ ◆ ◆ Alfentanil ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Levofloxacin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Aspirin ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Linezolid ◆ ◆ ◆ ◆ ◆ ◆ Buprenorphine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Lymecycline ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Celecoxib ◆ ◆ ◆ ◆ ◆ ◆ ◆ Meropenem ◆ ◆ ◆ ◆ ◆ ◆ Codeine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ for distribution. for Methenamine ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dexketoprofen ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Metronidazole ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Dextropropoxyphene ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ ◆ Moxifloxacin ◆ ◆ ◆
    [Show full text]
  • Benign Prostatic Hyperplasia
    Benign Prostatic Hyperplasia (BPH) Treatments Therapeutic Class Review (TCR) November 18, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected].
    [Show full text]
  • Silodosin I-PSS Were 66.8% with Silodosin and 65.4% with Tamsulosin
    VOLUME 41 : NUMBER 4 : AUGUST 2018 NEW DRUGS who had an improvement of at least 25% in the Silodosin I-PSS were 66.8% with silodosin and 65.4% with tamsulosin. These results were significantly better Approved indication: benign prostatic hypertrophy than the 50.8% response rate to placebo. While Aust Prescr 2018;41:129–30 Urorec (Mayne) 44–45% of the men were ‘delighted, pleased or https://doi.org/10.18773/ 4 mg and 8 mg capsules mostly satisfied’ with the active treatments, only austprescr.2018.030 Australian Medicines Handbook section 13.2.1 34% of the placebo group agreed.2 First published 12 June 2018 Benign prostatic hyperplasia can cause lower urinary Silodosin was generally well tolerated, but tract symptoms such as slow urine flow, nocturia caused more adverse effects than placebo. In the and incomplete emptying of the bladder. If these placebo-controlled trials, 6.4% of the silodosin group symptoms are sufficiently bothersome as to require withdrew because of adverse events compared treatment, selective alpha-blockers such as alfuzosin with 2.2% of the placebo group. Problems that were and tamsulosin are one option. These drugs block more frequent with silodosin included dizziness, orthostatic hypotension, diarrhoea and headache. alpha1 adrenoreceptors in the smooth muscle of the prostate and bladder to reduce resistance and so A major difference between silodosin and placebo improve urinary flow. Silodosin is another selective was the adverse effect of retrograde ejaculation 1 alpha-blocker. It has much greater affinity for the (28.1% vs 0.9%). This abnormal ejaculation is thought to be a consequence of the selective blockade of alpha1A receptor than the alpha1B receptor found in vascular smooth muscle.
    [Show full text]
  • Alpha Blockers
    Alfuzosin, Silodosin, Tamsulosin/Clinically Uroselective Alpha1-Adrenergic Blockers: Recommendations for Use October 2010 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The product information should be consulted for detailed prescribing information. Issue Is there a preference to using a clinically uroselective alpha1-adrenergic blocker over a non-uroselective alpha1-adrenergic blocker for the management of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Background Of the available non-uroselective alpha1-adrenergic blockers, doxazosin, prazosin, and terazosin are listed on the VA National Formulary (VANF); alfuzosin, silodosin, and tamsulosin are considered clinically uroselective alpha1-blockers , of which tamsulosin is available on the VANF for use in patients with LUTS due to BPH. Summary of Clinical Evidence1-6 All alpha1-blockers have been shown to improve LUTS associated with BPH (recommended doses for BPH are doxazosin 4 to 8mg once daily, prazosin 2mg twice daily, terazosin 5 to 10mg once daily; lower doses have also been effective) although the American Urological Association (AUA) guidelines for BPH state there are insufficient data to support the use of prazosin in BPH. There is no evidence that alfuzosin, silodosin, or tamsulosin provide benefit in patients who have not responded to an adequate trial with a non-uroselective alpha1-blocker. It is unknown whether the clinically uroselective alpha1-blockers offer an advantage in patients who are at risk for falls. Based on meta-analyses by the AUA, alfuzosin and tamsulosin were found to have significantly less dizziness than terazosin but not doxazosin. In addition, the change in blood pressure with doxazosin or terazosin has been found to be clinically insignificant in patients with BPH who are either normotensive or have hypertension (HTN) that is well-controlled with pharmacologic agents.
    [Show full text]